• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/26 4:28:56 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email
    8-K
    0001544227false0001544227us-gaap:CommonStockMember2026-05-142026-05-1400015442272026-05-142026-05-140001544227tpst:SeriesAJuniorParticipatingPreferredPurchaseRightsMember2026-05-142026-05-14

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2026

     

     

    Tempest Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-35890

    45-1472564

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2000 Sierra Point Parkway, Suite 400

     

    Brisbane, California

     

    94005

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (415) 798-8589

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    TPST

     

    The Nasdaq Stock Market LLC

    Series A Junior Participating Preferred Purchase Rights

     

    N/A

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 14, 2026, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and other business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    The foregoing information (including Exhibit 99.1 hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press release dated May 14, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    TEMPEST THERAPEUTICS, INC.

     

     

     

     

    Date:

    May 14, 2026

    By:

    /s/ Matthew Angel

     

     

    Name:

    Matthew Angel

     

     

    Title:

    Chief Executive Officer

     


    Get the next $TPST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by Scotiabank

    Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

    4/10/25 8:50:49 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

    4/10/25 8:03:29 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/2/24 4:15:14 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

    BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the "Board"), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board. "Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers," said Matt Angel, Ph.D., President and CEO of Tempest. "The addition of Drake and John to the Boa

    6/4/26 4:37:05 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

    BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,172,414 shares of the Company's common stock originally issued by the Company on November 26, 2025, having an original exercise price of $3.50 per share, at a reduced exercise price of $1.73 per share. The closing of the warrant exercise transaction is expected to occur on or about May 29, 2025, subject to satisfaction of

    5/29/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

    Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center ("AGCTC") as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "We made strong progress in the first

    5/14/26 4:15:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Trojanowski Justin

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    4/2/26 5:00:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Maestas Nicholas

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    4/2/26 5:00:35 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    3/25/26 5:32:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    SEC Filings

    View All

    Tempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    6/4/26 5:00:25 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Tempest Therapeutics Inc.

    PRE 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)

    5/29/26 5:06:06 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    5/29/26 5:01:10 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Leadership Updates

    Live Leadership Updates

    View All

    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

    BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the "Board"), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board. "Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers," said Matt Angel, Ph.D., President and CEO of Tempest. "The addition of Drake and John to the Boa

    6/4/26 4:37:05 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

    Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center ("AGCTC") as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "We made strong progress in the first

    5/14/26 4:15:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    5/13/24 4:54:01 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    2/14/24 6:49:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Extends Limited Duration Stockholder Rights Plan

    BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

    10/10/24 7:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

    21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

    6/20/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care